Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase
- 1 March 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3) , 1194-1203
Abstract
GS-9160 is a novel and potent inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase (IN) that specifically targets the process of strand transfer. It is an authentic inhibitor of HIV-1 integration, since treatment of infected cells results in an elevation of two-long terminal repeat circles and a decrease of integration junctions. GS-9160 has potent and selective antiviral activity in primary human T lymphocytes producing a 50% effective concentration (EC50) of ∼2 nM, with a selectivity index (50% cytotoxic concentration/EC50) of ∼2,000. The antiviral potency of GS-9160 decreased by 6- to 10-fold in the presence of human serum. The antiviral activity of GS-9160 is synergistic in combination with representatives from three different classes of antiviral drugs, namely HIV-1 protease inhibitors, nonnucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Viral resistance selections performed with GS-9160 yielded a novel pattern of mutations within the catalytic core domain of IN; E92V emerged initially, followed by L74M. While E92V as a single mutant conferred 12-fold resistance against GS-9160, L74M had no effect as a single mutant. Together, these mutations conferred 67-fold resistance to GS-9160, indicating that L74M may potentiate the resistance caused by E92V. The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued.Keywords
This publication has 33 references indexed in Scilit:
- Modeling, Analysis, and Validation of a Novel HIV Integrase Structure Provide Insights into the Binding Modes of Potent Integrase InhibitorsJournal of Molecular Biology, 2008
- Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137Antimicrobial Agents and Chemotherapy, 2008
- Tricyclic HIV integrase inhibitors: Potent and orally bioavailable C5-aza analogsBioorganic & Medicinal Chemistry Letters, 2008
- Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Journal of Virology, 2008
- A potent and orally active HIV-1 integrase inhibitorBioorganic & Medicinal Chemistry Letters, 2007
- Effect of substitution on novel tricyclic HIV-1 integrase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ringBioorganic & Medicinal Chemistry Letters, 2006
- Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Hiv integrase: a target for aids therapeuticsTrends in Biotechnology, 1997
- A three-dimensional model to analyze drug-drug interactionsAntiviral Research, 1990